Eli Lilly and Co (LLY) FY2025Q4 Earning Prediction
Eli Lilly and Co (LLY) is set to release its FY2025Q4 earnings performance on 02/04 06:45:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 17.87B and an earnings per share (EPS) of 6.99 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The earnings forecast anticipates a 'Beat' driven by strong demand for key products, strategic investments, and regulatory tailwinds.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Key Fact Data Drivers:
- Product Momentum:
Zepbound/Mounjaro Dominance: Continued strong demand for GLP-1 agonists, with Zepbound’s multi-dose pen approval imminent (Q1 2026) and Phase 3 TOGETHER-PsA trial success demonstrating dual efficacy in obesity and psoriatic arthritis.
FDA Breakthrough Designation: Sofetabart mipitecan for ovarian cancer reinforces pipeline credibility.
- Strategic Expansion:
Manufacturing Investment: $ 3.5B Pennsylvania facility bolsters long-term capacity for obesity therapies.
AI Partnerships: Collaboration with Nvidia ($1B investment) accelerates drug discovery, though near-term revenue impact is limited.
- Regulatory Tailwinds:
FDA Safety Update: Removal of suicide risk warnings for GLP-1 drugs (Zepbound, Wegovy) reduces liability concerns.
Medicare/Trump Deal: Expanded access offsets price cuts via volume growth, per JPMorgan analysis.
- Competitive Positioning:
Acquisitions: Ventyx Biosciences ($ 1.2B) adds immunology/metabolic assets. Rumored interest in Abivax signals pipeline diversification.
International Growth: Pre-generic market capture in India and EU expansion mitigate near-term competition.
Consensus Context:
- Stock price (+18% vs. S&P 500’s +1%) reflects sky-high expectations. Fact data supports revenue/EPS beats, but valuation limits "Strong Beat" likelihood.
Tactical Strategy Recommendations
- Options: Buy short-dated (Feb 2026) $1,050 calls for leverage on beat momentum.
- Pairs Trade: Long LLY/short Novo Nordisk (NVO) to capitalize on Lilly’s AI-driven pipeline edge.
- Hedge: Sell upside calls against shares to monetize elevated IV (~35%).
Rationale: Fact data supports execution, but high expectations demand selectivity. Focus on Zepbound’s commercial traction and AI-driven R&D efficiency as catalysts.
Earnings Surprise Analysis
LLY Transcript
The earnings call summary reflects strong financial performance, with significant revenue and EPS growth, increased guidance, and positive market trends. Product development updates, especially for orforglipron, indicate potential future growth. The Q&A section reveals optimism about new product launches and market expansion, despite some unanswered questions about cash pay dynamics. The company's strategic reinvestments and shareholder returns further support a positive outlook, although the lack of specific guidance metrics and management's evasive responses slightly temper the sentiment.
The earnings call summary and Q&A indicate strong financial performance, strategic advancements, and positive market reception. Key highlights include raised revenue and EPS guidance, new trials and product launches, and a focus on market expansion. The management's responses in the Q&A were generally well-received, with analysts showing interest in the company's innovation and market strategies. Despite some vague responses, the overall sentiment is positive, supported by growth prospects and strategic initiatives.
LLY Report
Frequently Asked Questions
What is the Eli Lilly and Co FY2025Q4 Earnings Release Date and Time?
Eli Lilly and Co (LLY) is scheduled to release its FY2025Q4 earnings report onFeb 4, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Eli Lilly and Co FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 17.87B in revenue and an EPS of 6.99 for Eli Lilly and Co's FY2025Q4.
What Does Intellectia's AI Predict for Eli Lilly and Co FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a Beat forEli Lilly and Co's FY2025Q4 earnings, with a prediction date of Feb 4, 2026. Eli Lilly and Co The earnings forecast anticipates a 'Beat' driven by strong demand for key products, strategic investments, and regulatory tailwinds.
How Can I Use This Earnings Prediction to Trade LLY Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 4, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Eli Lilly and Co FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
